UA95922C2 - Glucuronate salt of a piperazine compound - Google Patents

Glucuronate salt of a piperazine compound

Info

Publication number
UA95922C2
UA95922C2 UAA200804630A UAA200804630A UA95922C2 UA 95922 C2 UA95922 C2 UA 95922C2 UA A200804630 A UAA200804630 A UA A200804630A UA A200804630 A UAA200804630 A UA A200804630A UA 95922 C2 UA95922 C2 UA 95922C2
Authority
UA
Ukraine
Prior art keywords
piperazine compound
glucuronate salt
salt form
present
salt
Prior art date
Application number
UAA200804630A
Other languages
English (en)
Ukrainian (uk)
Inventor
Субодх С. Дешмук
Кадум Али
Кристофер Р. Диорио
Эрик С. Эрншпергер
Махди Б. Фавзи
Суэд Музафар Шах
Махмуд Мирмехраби
Original Assignee
Эббот Хелскеа Продактс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37603202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA95922(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эббот Хелскеа Продактс Б.В. filed Critical Эббот Хелскеа Продактс Б.В.
Publication of UA95922C2 publication Critical patent/UA95922C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

В этом изобретении предлагается солевая форма и композиции на ее основе, которая может использоваться как модулятор одного или нескольких GPCR и имеет необходимые для этого свойства.Изобретение также предлагает способ получения указанной солевой формы, которая происходит от 8-{4-[3-(5-фтор-1Н-индол-3-ил)-пропил]-пиперазин-1-ил}-2-метил-4Н-бенз[1,4]оксазин-3-она и глюкуроновой кислоты.
UAA200804630A 2005-09-12 2006-12-09 Glucuronate salt of a piperazine compound UA95922C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71616705P 2005-09-12 2005-09-12

Publications (1)

Publication Number Publication Date
UA95922C2 true UA95922C2 (en) 2011-09-26

Family

ID=37603202

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200804630A UA95922C2 (en) 2005-09-12 2006-12-09 Glucuronate salt of a piperazine compound

Country Status (20)

Country Link
US (1) US7595310B2 (ru)
EP (1) EP1940830A1 (ru)
JP (1) JP2009507921A (ru)
KR (1) KR20080045285A (ru)
CN (1) CN101287730B (ru)
AR (1) AR056506A1 (ru)
AU (1) AU2006291058B2 (ru)
BR (1) BRPI0615853A2 (ru)
CA (1) CA2620755A1 (ru)
EA (1) EA014942B1 (ru)
GT (1) GT200600414A (ru)
IL (1) IL189809A0 (ru)
MY (1) MY144782A (ru)
NO (1) NO20081809L (ru)
PE (1) PE20070433A1 (ru)
SA (1) SA06270329B1 (ru)
TW (1) TW200800974A (ru)
UA (1) UA95922C2 (ru)
WO (1) WO2007033191A1 (ru)
ZA (1) ZA200802310B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070523A1 (es) 2005-09-12 2007-06-28 Wyeth Corp Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
KR20150023937A (ko) 2007-05-11 2015-03-05 리히터 게데온 닐트. 카르바모일-사이클로헥산 유도체의 신규한 용매화물 및 결정 형태
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
SG192507A1 (en) 2008-07-16 2013-08-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
US4687772A (en) * 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4771053A (en) * 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US5162375A (en) * 1988-05-06 1992-11-10 Beecham Group P.L.C. Treatment of neuronal degeneration with 5HT1A agonists
DE4135551A1 (de) 1991-08-31 1993-03-04 Schering Ag Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen
US5824680A (en) * 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
US5716960A (en) * 1995-01-13 1998-02-10 U.S. Bioscience Inc. And Individuals Crystalline trimetrexate salts and the process for making the same
SE9900190D0 (sv) 1999-01-22 1999-01-22 Astra Ab New compounds
DE19730989A1 (de) * 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate
AU736596B2 (en) * 1997-07-25 2001-08-02 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
HN1999000146A (es) 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
BR0013498A (pt) * 1999-08-23 2002-05-14 Solvay Pharm Bv Composto, método para a preparação do mesmo, composição farmacêutica, e, métodos para a preparação da mesma e para o tratamento de distúrbios do snc
SK10552002A3 (sk) 2000-01-19 2002-12-03 Akzo Nobel N.V. Kombinácia a jej použitie
AR032712A1 (es) * 2001-02-21 2003-11-19 Solvay Pharm Bv Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
AU2004266233A1 (en) * 2003-08-13 2005-03-03 Amgen, Inc. Melanin concentrating hormone receptor antagonist
US20050197347A1 (en) 2003-12-18 2005-09-08 Judith Aronhime Polymorphic form B2 of ziprasidone base
GT200600416A (es) * 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
PE20070523A1 (es) 2005-09-12 2007-06-28 Wyeth Corp Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona

Also Published As

Publication number Publication date
ZA200802310B (en) 2008-12-31
EA014942B1 (ru) 2011-04-29
EP1940830A1 (en) 2008-07-09
TW200800974A (en) 2008-01-01
AU2006291058A1 (en) 2007-03-22
BRPI0615853A2 (pt) 2011-05-31
CA2620755A1 (en) 2007-03-22
EA200800810A1 (ru) 2008-10-30
JP2009507921A (ja) 2009-02-26
US7595310B2 (en) 2009-09-29
AU2006291058B2 (en) 2011-09-08
MY144782A (en) 2011-11-15
NO20081809L (no) 2008-04-14
WO2007033191A1 (en) 2007-03-22
KR20080045285A (ko) 2008-05-22
CN101287730B (zh) 2012-03-07
PE20070433A1 (es) 2007-04-24
AR056506A1 (es) 2007-10-10
IL189809A0 (en) 2008-08-07
CN101287730A (zh) 2008-10-15
US20070254876A1 (en) 2007-11-01
GT200600414A (es) 2007-09-20
SA06270329B1 (ar) 2010-06-15

Similar Documents

Publication Publication Date Title
UA95922C2 (en) Glucuronate salt of a piperazine compound
TW200420641A (en) Resin compositions
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
NO20044882L (no) Acyl-4-karboksylfenylurinstoffderivater, deres fremstilling og anvendelse
AU2002319814A1 (en) Substituted 1h-dihydropyrazoles, their preparation and use
WO2004074244A3 (en) Pyrimidine compounds
WO2005070884A3 (en) Heterocyclic compounds useful as growth hormone secretagogues
MY152283A (en) Polo-like kinase inhibitirs
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
RS20090438A (en) Triazol tropane derivatives as ccr5 moudlators
AU2003228770A1 (en) Substituted pyrazolopyrimidines
MX2010001576A (es) Compuestos 3´sustituidos que tienen afinidad con el receptor 5-hidroxitriptamina 6 (5-ht6).
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
WO2006100081A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
WO2007019191A3 (en) Thiazolopyrimidine kinase inhibitors
PL1831152T3 (pl) Pochodne tetraliny i indanu oraz ich zastosowanie jako antagonistów 5-HT
AU2003228674A1 (en) Muscarinic antagonists
MXPA02011370A (es) Iminoazinas substituidas.
MX2009008324A (es) Compuestos 6´-sustituidos que tienen afinidad con el receptor de 5-hidroxitriptamina-6.
WO2004112704A3 (en) Substituted piperidine compounds and methods of their use
WO2008147812A3 (en) 4' substituted compounds having 5-ht6 receptor affinity
WO2007134149A3 (en) 3,4-dihydro-2h-benzo[1,4]oxazine and thiazine derivatives as cetp inhibitors
WO2008116185A3 (en) Substituted pyrimidines as adenosine receptor antagonists
GEP20074256B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing
WO2006031929A3 (en) Thiazolopyridine kinase inhibitors